Andere Sprachen Eris Lifesciences Limited

Aktien

A2DU61

INE406M01024

ERIS

Pharmazeutika

Markt geschlossen - NSE India S.E. Andere Börsenplätze 12:49:37 17.01.2025			% 5 Tage	% 1. Jan.
1.290,15 ^INR	-0,78 %		+0,21 %	-6,08 %

25.10.	Eris Lifesciences Limited, H1 2025 Earnings Call, Oct 25, 2024
25.10.	Eris Lifesciences Limited meldet die Ergebnisse für das zweite Quartal und die sechs Monate bis zum 30. September 2024	CI

Andere Sprachen

Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	25.10.24
Eris Lifesciences Limited completed the acquisition of Chemman Labs Private Limited.	14.10.24
India's Biocon posts Q1 profit rise on sale of branded formulations business	08.08.24
Eris Lifesciences' Consolidated Net Profit Slips in Fiscal Q1	06.08.24
Eris Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	02.08.24
Eris Lifesciences Limited agreed to acquire Chemman Labs Private Limited for an enterprise value of INR 1.1 billion.	02.08.24
Eris Lifesciences Completes Acquisition of 19% Stake in Swiss Parenterals	12.06.24
Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit	22.05.24
Eris Lifesciences Gets Board Nod to Raise Up to INR12.50 Billion Via Bond Sale	21.05.24
Eris Lifesciences Limited completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel.	18.04.24
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03.04.24
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15.03.24
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14.03.24
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14.03.24
Eris Lifesciences Limited agreed to acquire additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel for INR 2.4 billion.	14.03.24
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	14.03.24
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	16.02.24
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	15.02.24
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	13.02.24
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13.02.24
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	13.02.24
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	08.02.24
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	10.11.23
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations, India Business Units	09.11.23
Indian shares set to open higher tracking Asian peers	09.11.23

Werden Sie Mitglied, um Zugang zu mehr Nachrichten zu erhalten.

100% kostenlose Registrierung

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Eris Lifesciences Limited

Aktien

A2DU61

INE406M01024

ERIS

Pharmazeutika

Andere Sprachen

Filter